ArticleCancers2023

Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer.

Cheol-Kyu Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.